Peter Lawson
Stock Analyst at Barclays
(1.40)
# 3,577
Out of 5,090 analysts
99
Total ratings
39.53%
Success rate
-10.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $19.75 | +11.42% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $100.48 | +0.52% | 1 | Oct 29, 2025 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $331.27 | +16.22% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $35.95 | +11.27% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $18.32 | +36.46% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $10.50 | -71.41% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $44.40 | -9.90% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.38 | +117.39% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.11 | +81.00% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $5.89 | +69.78% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.22 | +80.18% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $18.05 | -66.76% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $12.02 | -8.49% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $12.62 | +26.83% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $7.19 | +108.62% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $25.26 | -44.58% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.17 | +155.47% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.09 | +175.23% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.26 | +216.61% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $78.51 | -23.57% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $8.00 | +112.63% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $40.24 | +64.02% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $18.00 | +72.22% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $9.88 | +31.58% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.54 | +224.68% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.09 | -14.43% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $127.80 | +185.60% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.43 | +67.70% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $57.50 | +682.68% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.44 | +1,744.26% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $58.85 | -23.53% | 2 | Jan 23, 2018 |
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $19.75
Upside: +11.42%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $100.48
Upside: +0.52%
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $331.27
Upside: +16.22%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $35.95
Upside: +11.27%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $18.32
Upside: +36.46%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $10.50
Upside: -71.41%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $44.40
Upside: -9.90%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.38
Upside: +117.39%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.11
Upside: +81.00%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $5.89
Upside: +69.78%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.22
Upside: +80.18%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $18.05
Upside: -66.76%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $12.02
Upside: -8.49%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $12.62
Upside: +26.83%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.19
Upside: +108.62%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $25.26
Upside: -44.58%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.17
Upside: +155.47%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.09
Upside: +175.23%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.26
Upside: +216.61%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $78.51
Upside: -23.57%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $8.00
Upside: +112.63%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $40.24
Upside: +64.02%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $18.00
Upside: +72.22%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $9.88
Upside: +31.58%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.54
Upside: +224.68%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.09
Upside: -14.43%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $127.80
Upside: +185.60%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.43
Upside: +67.70%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $57.50
Upside: +682.68%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.44
Upside: +1,744.26%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $58.85
Upside: -23.53%